Mem Inst Oswaldo Cruz, Rio de Janeiro, VOLUME 117 | 2022
Perspective

Transforming growth factor-β as a therapeutic target for the cardiac damage of Chagas disease

Mariana Caldas Waghabi1,+, Roberto Rodrigues Ferreira1,4, Rayane da Silva Abreu1, Wim Degrave1, Elen Mello de Souza2, Sabine Bailly3, Jean-Jacques Feige3, Tania C de Araújo-Jorge4

1Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Genômica Funcional e Bioinformática, Rio de Janeiro, RJ, Brasil
2Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Virologia Molecular, Rio de Janeiro, RJ, Brasil
3Institut National de la Santé et de la Recherche Médicale, Biology of Cancer and Infection Laboratory, Grenoble, France
4Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Rio de Janeiro, RJ, Brasil

DOI: 10.1590/0074-02760210395
1029 views 244 downloads
ABSTRACT

Transforming growth factor beta (TGF-β) is deeply involved on the pathogenesis of Chagas disease. Our group has been investigating the participation of this pleiotropic cytokine in different aspects of Chagas disease over the last 20 years. Important observations have been made, such as: (i) the ability of Trypanosoma cruzi in activating latent TGF-β; (ii) the potential involvement of TGF-β pathway on T. cruzi invasion of host cells; (iii) association of TGF-β with parasite intracellular replication; (iv) cardiac fibrosis development and maintenance; (v) disruption of Connexin-43 plaque structures and (vi) inflammation and immune response. In this perspective article we intend to discuss the advances of the potential use of new therapies targeting TGF-β to treat the cardiac alterations of Chagas disease-affected patients.

REFERENCES
01. de Araújo-Jorge TC, Waghabi MC, Hasslocher-Moreno AM, Xavier S, Higuchi MDL, Keramidas M, et al. Implication of transforming growth factor-b 1 in Chagas disease myocardiopathy. J Infect Dis. 2002; 186: 1823-8.

02. de Andrade JP, Marin Neto JA, de Paola AAV, Vilas-Boas F, Oliveira GMM, Bacal F, et al. I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy. Arq Bras Cardiol. 2011; 97: 1-48.

03. Massagué J. TGFβ s ignalling i n c ontext. Nat R ev Mol C ell Biol. 2012; 13: 616-30.

04. Ferreira RR, Waghabi MC, Bailly S, Feige JJ, Hasslocher-Moreno AM, Saraiva RM, et al. Chagas disease immunogenetics and the search for disease biomarkers: insights from TGF-beta studies. Front Cell Infect Microbiol. 2021; doi: 10.3389/fcimb.2021.767576.

05. de Araújo-Jorge TC, Waghabi MC, Bailly S, Feige J. The TGF-β pathway as an emerging target for Chagas disease therapy. Clin Pharmacol Ther. 2012; 92: 613-21.

06. Saraiva RM, Waghabi MC, Vilela MF, Madeira FS, da Silva GMS, Xavier SS, et al. Predictive value of transforming growth factor-β1 in Chagas disease: towards a biomarker surrogate of clinical outcome. Trans R Soc Trop Med Hyg. 2013; 107: 518-25.

07. Nogueira LG, Frade AF, Ianni BM, Laugier L, Pissetti CW, Cabantous S, et al. Functional IL18 polymorphism and susceptibility to chronic Chagas disease. Cytokine 2015; 73(1): 79-83.

08. Calzada JE, Beraun Y, Gonzalez CI, Martın J. Cytokine transforming growth factor beta 1 (TGF b 1) gene polymorphisms and Chagas disease susceptibility in Peruvian and Colombian patients. Cytokine. 2009; 45: 149-53.

09. Ferreira FF, Madeira FS, Alves GF, Chambela MC, Vaz Curvo EO, Moreira AS, et el. TGF-β polymorphisms are a risk fator for Chagas disease. Dis Markers. 2018; 2018: 4579198.

10. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Hum Mol Genet. 1999; 8(1): 93-7.

11. Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011; 39(6): 916-24.

12. Waghabi MC, de Souza EM, de Oliveira GM, Keramidas M, Feige J, de Araújo-Jorge TC, et al. Pharmacological inhibition of transforming growth factor beta signaling decreases infection and prevents heart damage in acute Chagas’ disease. Antimicrob Agents Chemother. 2009; 53: 4694-4701.

13. de Oliveira FL, Souza EM, de Oliveira GM, de Araújo-Jorge, TC, Degrave WM, Feige J, et al. Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl Trop Dis. 2012; 6: e1696.

14. Cutrullis RA, Poklepovich TJ, Postan M, Freilij HL, Petray PB. Immunomodulatory and anti-fibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosoma cruzi infection. Int Immunopharmacol. 2011; 11(8): 1024-31.

15. Ferreira RR, Abreu RS, Vilar-Pereira G, Degrave W, Meuser-Batista M, Ferreira NVC, et al. TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a preclinical study of chronic Chagas’ heart disease. PLoS Negl Trop Dis. 2019; 13(7): e0007602.

16. Chen Y, Lüttmann FF, Schoger E, Schöler HR, Zelarayán LC, Kim KP, et al. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice. Science. 2021; 373(6562): 1537-40.

17. Fernández-Ruiz I. Rejuvenating cardiomyocytes facilitates heart regeneration. Nat Rev Cardiol. 2021; 18: 807.

+ Corresponding author: mariana@ioc.fiocruz.br
ORCID https://orcid.org/0000-0002-1205-9507
Received 17 December 2021
Accepted 20 December 2021

Our Location

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco 
sala 201, Manguinhos, 21040-900 
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This email address is being protected from spambots. You need JavaScript enabled to view it.

Support Program

ioc

fiocruz 
faperj cnpq capes